Eric David
About Eric David
Eric David serves as the CEO of Gene Therapy at BridgeBio, where he has worked since 2018. He holds a BA from Amherst College, a JD from Columbia Law School, and an MD from Columbia University Vagelos College of Physicians and Surgeons.
Current Role at BridgeBio
Eric David serves as the CEO of Gene Therapy at BridgeBio, a position he has held since 2018. In this role, he oversees the development and implementation of gene therapy initiatives within the organization. His leadership is focused on advancing innovative treatments and therapies that address genetic disorders. Based in San Diego, California, he contributes to BridgeBio's mission of transforming the lives of patients through scientific advancements.
Previous Experience at Organovo Holdings, Inc.
Prior to his role at BridgeBio, Eric David co-founded Organovo Holdings, Inc. and served as the Chief Strategy Officer and Executive Vice President of Preclinical Development from 2012 to 2017. During his tenure, he played a key role in the strategic direction and development of the company’s innovative bioprinting technologies, which aimed to revolutionize the field of regenerative medicine. His experience at Organovo contributed to his expertise in the biotechnology sector.
Educational Background
Eric David holds a Bachelor of Arts degree in Physics and Fine Arts from Amherst College, where he studied from 1989 to 1993. He furthered his education at Columbia University Vagelos College of Physicians and Surgeons, earning a Doctor of Medicine (MD) from 1998 to 2002. Additionally, he obtained a Juris Doctor (JD) from Columbia Law School, focusing on Intellectual Property, Environmental Law, and Healthcare Law, from 1993 to 1996. This diverse educational background supports his multifaceted approach in the healthcare and biotechnology fields.
Professional Experience in Healthcare
Eric David has extensive experience in the healthcare sector. He worked as an Assistant Chief Resident in Internal Medicine at New York Presbyterian Hospital from 2002 to 2005. Following this, he served as an Associate Principal at McKinsey & Co from 2005 to 2012, where he provided strategic consulting services to healthcare organizations. Additionally, he was a Board Member at HealthCare Chaplaincy Network from 2016 to 2018, contributing to initiatives that support patients and families in healthcare settings.